EE313 Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar

This study aims to calculate savings generated from the switch of the reference ranibizumab molecule, to a ranibizumab biosimilar, and explore how savings could be reinvested.

Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, I. Rickard, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research